New and recently funded Medical Startups
1
Country: UK | Funding: $2.7B
Isomorphic Labs is a spin-off of Google DeepMind, developing and designing drugs based on the AlphaFold platform, which predicts protein structures. The company has created powerful predictive and generative AI models that simulate complex biological phenomena to aid in the development of new molecules, predicting drug effectiveness, and creating innovative drugs to treat and cure some of the world's most devastating diseases. The company also provides scientists with the freely available AlphaFold Protein Structure Database, which gives open access to over 200 million protein structure predictions to accelerate scientific research.
Isomorphic Labs is a spin-off of Google DeepMind, developing and designing drugs based on the AlphaFold platform, which predicts protein structures. The company has created powerful predictive and generative AI models that simulate complex biological phenomena to aid in the development of new molecules, predicting drug effectiveness, and creating innovative drugs to treat and cure some of the world's most devastating diseases. The company also provides scientists with the freely available AlphaFold Protein Structure Database, which gives open access to over 200 million protein structure predictions to accelerate scientific research.
2
Country: USA | Funding: $1B
Ro is a telehealth startup that operates digital health clinics for men’s and women’s health, in particular obesity. Ro patients fill out a dynamic online visit answering questions about their health, lifestyle, medical history, and symptoms. A physician then reviews the results and prescribes medication if appropriate. Medications are shipped directly to the patient's home. With a nationwide provider network, in-home care API, and proprietary pharmacy distribution centers, Ro seamlessly connects telehealth, diagnostics, and pharmacy services to provide high-quality, affordable healthcare without the need for insurance.
Ro is a telehealth startup that operates digital health clinics for men’s and women’s health, in particular obesity. Ro patients fill out a dynamic online visit answering questions about their health, lifestyle, medical history, and symptoms. A physician then reviews the results and prescribes medication if appropriate. Medications are shipped directly to the patient's home. With a nationwide provider network, in-home care API, and proprietary pharmacy distribution centers, Ro seamlessly connects telehealth, diagnostics, and pharmacy services to provide high-quality, affordable healthcare without the need for insurance.
3
Country: USA | Funding: $29.9M
Dandelion Health AI develops a clinical data and artificial intelligence platform that enables researchers to analyze patient data.
Dandelion Health AI develops a clinical data and artificial intelligence platform that enables researchers to analyze patient data.
4
Country: USA | Funding: A$18.7M
Diagnose and monitor neurological disorders such as autism using advanced facial recognition and AI techniques.
Diagnose and monitor neurological disorders such as autism using advanced facial recognition and AI techniques.
5
Country: UK | Funding: $475.7M
CellCentric is a biotechnology company that develops small molecule therapies to treat cancer and multiple myeloma.
CellCentric is a biotechnology company that develops small molecule therapies to treat cancer and multiple myeloma.
6
Country: USA | Funding: $135.5M
QurAlis specializes in developing and developing precision therapies for amyotrophic lateral sclerosis (ALS), based on its recent breakthrough discovery of the links between STATHMIN-2 and TDP-43. Company's lead therapeutics are QRL-201 - first-in-class molecule for the treatment of ALS that targets STMN2 expression in ALS patients, and QRL-101 - potential best-in-class selective activator of the Kv7.2/7.3 ion channel for the treatment of disease progression caused by hyperexcitability in ALS, as well as for the treatment of epilepsy and pain. Beyond ALS, QurAlis is developing a robust precision medicine portfolio for the treatment of neurodegenerative and neurological diseases, such as epilepsy, pain, frontotemporal dementia, fragile X syndrome, and progressive supranuclear palsy.
QurAlis specializes in developing and developing precision therapies for amyotrophic lateral sclerosis (ALS), based on its recent breakthrough discovery of the links between STATHMIN-2 and TDP-43. Company's lead therapeutics are QRL-201 - first-in-class molecule for the treatment of ALS that targets STMN2 expression in ALS patients, and QRL-101 - potential best-in-class selective activator of the Kv7.2/7.3 ion channel for the treatment of disease progression caused by hyperexcitability in ALS, as well as for the treatment of epilepsy and pain. Beyond ALS, QurAlis is developing a robust precision medicine portfolio for the treatment of neurodegenerative and neurological diseases, such as epilepsy, pain, frontotemporal dementia, fragile X syndrome, and progressive supranuclear palsy.
7
Country: Australia | Funding: $12.1M
Baymatob is developing an AI-powered maternal-foetal early warning platform. Its flagship device Oli uses sensors and AI to identify mothers who are at high risk of developing abnormal postpartum haemorrhage (PPH) before giving birth.
Baymatob is developing an AI-powered maternal-foetal early warning platform. Its flagship device Oli uses sensors and AI to identify mothers who are at high risk of developing abnormal postpartum haemorrhage (PPH) before giving birth.
8
Country: Australia | Funding: $18.7M
Lumonus is a healthcare company that offers Radiation Oncology, Radiation Therapy, and Cancer treatment technology-enabled services.
Lumonus is a healthcare company that offers Radiation Oncology, Radiation Therapy, and Cancer treatment technology-enabled services.
9
Country: China | Funding: $250M
Syneron leverages AI through its proprietary Synova macrocyclic peptide platform. The company describes macrocyclic peptides as a “goldilocks” drug class due to their ability to bridge the gap between small molecules and biologics, enabling the targeting of traditionally difficult disease pathways. Using this technology Syneron develops a pipeline across multiple indications in oncology, autoimmune, metabolic and rare disease programs.
Syneron leverages AI through its proprietary Synova macrocyclic peptide platform. The company describes macrocyclic peptides as a “goldilocks” drug class due to their ability to bridge the gap between small molecules and biologics, enabling the targeting of traditionally difficult disease pathways. Using this technology Syneron develops a pipeline across multiple indications in oncology, autoimmune, metabolic and rare disease programs.
10
Country: USA | Funding: $121.5M
Stipple Bio is a biotechnology company that offers cellular profiling and target discovery with epitope resolution. Company's bespoke Pointillist platform is a modality-agnostic system that identifies tumor-specific cell surface epitopes - sections of antigens bound by an antibody’s paratope or a T-cell receptor—for development into potential cancer therapies. It's lead asset STP-100 is an antibody-drug conjugate (ADC) leveraging tumor-specific binders designed to avoid on-target and off-tumor toxicity.
Stipple Bio is a biotechnology company that offers cellular profiling and target discovery with epitope resolution. Company's bespoke Pointillist platform is a modality-agnostic system that identifies tumor-specific cell surface epitopes - sections of antigens bound by an antibody’s paratope or a T-cell receptor—for development into potential cancer therapies. It's lead asset STP-100 is an antibody-drug conjugate (ADC) leveraging tumor-specific binders designed to avoid on-target and off-tumor toxicity.
